Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Ohio State University Comprehensive Cancer Center
Emory University
Memorial Sloan Kettering Cancer Center
Institut Curie
University of Nebraska
Massachusetts General Hospital
Cedars-Sinai Medical Center
Université de Sherbrooke
Jiangxi Provincial Cancer Hospital
European Institute of Oncology
Sun Yat-sen University